These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 32518085

  • 1. CKD Increases Carbonylation of HDL and Is Associated with Impaired Antiaggregant Properties.
    Florens N, Calzada C, Lemoine S, Boulet MM, Guillot N, Barba C, Roux J, Delolme F, Page A, Poux JM, Laville M, Moulin P, Soulère L, Guebre-Egziabher F, Juillard L, Soulage CO.
    J Am Soc Nephrol; 2020 Jul; 31(7):1462-1477. PubMed ID: 32518085
    [Abstract] [Full Text] [Related]

  • 2. Two Toxic Lipid Aldehydes, 4-hydroxy-2-hexenal (4-HHE) and 4-hydroxy-2-nonenal (4-HNE), Accumulate in Patients with Chronic Kidney Disease.
    Soulage CO, Pelletier CC, Florens N, Lemoine S, Dubourg L, Juillard L, Guebre-Egziabher F.
    Toxins (Basel); 2020 Sep 03; 12(9):. PubMed ID: 32899405
    [Abstract] [Full Text] [Related]

  • 3. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
    Moradi H, Pahl MV, Elahimehr R, Vaziri ND.
    Transl Res; 2009 Feb 03; 153(2):77-85. PubMed ID: 19138652
    [Abstract] [Full Text] [Related]

  • 4. Plasma lipoproteins affect platelet malondialdehyde and thromboxane B2 production.
    Aviram M, Sirtori CR, Colli S, Maderna P, Morazzoni G, Tremoli E.
    Biochem Med; 1985 Aug 03; 34(1):29-36. PubMed ID: 4052061
    [Abstract] [Full Text] [Related]

  • 5. High-Density Lipoprotein Subfractions and Their Oxidized Subfraction Particles in Patients with Chronic Kidney Disease.
    Honda H, Hirano T, Ueda M, Kojima S, Mashiba S, Hayase Y, Michihata T, Shibata T.
    J Atheroscler Thromb; 2016 Aug 03; 23(1):81-94. PubMed ID: 26289085
    [Abstract] [Full Text] [Related]

  • 6. Glycoxidized HDL, HDL enriched with oxidized phospholipids and HDL from diabetic patients inhibit platelet function.
    Lê QH, El Alaoui M, Véricel E, Ségrestin B, Soulère L, Guichardant M, Lagarde M, Moulin P, Calzada C.
    J Clin Endocrinol Metab; 2015 May 03; 100(5):2006-14. PubMed ID: 25794249
    [Abstract] [Full Text] [Related]

  • 7. Acute coronary syndrome remodels the antiplatelet aggregation properties of HDL particle subclasses.
    Garcia C, Montée N, Faccini J, Series J, Meilhac O, Cantero AV, Le Faouder P, Elbaz M, Payrastre B, Vindis C.
    J Thromb Haemost; 2018 May 03; 16(5):933-945. PubMed ID: 29543379
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Platelet activation by oxidatively modified low density lipoproteins.
    Ardlie NG, Selley ML, Simons LA.
    Atherosclerosis; 1989 Apr 03; 76(2-3):117-24. PubMed ID: 2730708
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lysine modification of LDL or lipoprotein(a) by 4-hydroxynonenal or malondialdehyde decreases platelet serotonin secretion without affecting platelet aggregability and eicosanoid formation.
    Malle E, Ibovnik A, Leis HJ, Kostner GM, Verhallen PF, Sattler W.
    Arterioscler Thromb Vasc Biol; 1995 Mar 03; 15(3):377-84. PubMed ID: 7749848
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preβ1-high-density lipoprotein metabolism is delayed in patients with chronic kidney disease not on hemodialysis.
    Yamatani K, Hirayama S, Seino U, Hirayama A, Hori A, Suzuki K, Idei M, Kitahara M, Miida T.
    J Clin Lipidol; 2020 Mar 03; 14(5):730-739. PubMed ID: 32868248
    [Abstract] [Full Text] [Related]

  • 17. Paricalcitol effects on activities and metabolism of platelet activating factor and on inflammatory cytokines in hemodialysis patients.
    Verouti SN, Tsoupras AB, Alevizopoulou F, Demopoulos CA, Iatrou C.
    Int J Artif Organs; 2013 Feb 03; 36(2):87-96. PubMed ID: 23335378
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting.
    Breet NJ, de Jong C, Bos WJ, van Werkum JW, Bouman HJ, Kelder JC, Bergmeijer TO, Zijlstra F, Hackeng CM, Ten Berg JM.
    Thromb Haemost; 2014 Dec 03; 112(6):1174-81. PubMed ID: 25231776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.